What is it about?

In this paper, we describe a novel assay we developed to detect and quantify the copy numbers of PVT1 exons 4A, 4B, and 9 in diverse biological materials, including serum. This assay will ultimately prove useful as a screening or detection tool for diseases, such as certain cancers, where overexpression of PVT1 has been documented.

Featured Image

Why is it important?

Overexpression of PVT1 is now an established characteristic of many cancers, including prostate cancer. Detection and quantification of copy numbers of PVT1 exons 4A, 4B, or 9 in diseases where PVT1 is overexpressed may prove useful clinically for screening and detection of these diseases, especially earlier and non-invasively.


It is exciting to see a new assay that may ultimately solve the problem of accurately identifying prostate cancer non-invasively, and risk-stratification in prostate cancer. This will diminish overdiagnosis, and reduce unnecessary prostate biopsies.

Olorunseun Ogunwobi
City University of New York System

Read the Original

This page is a summary of: Copy number-based quantification assay for non-invasive detection of PVT1-derived transcripts, PLoS ONE, December 2019, PLOS, DOI: 10.1371/journal.pone.0226620.
You can read the full text:



The following have contributed to this page